Goserelin is an injectable gonadotropin releasing hormone agonist (GnRH agonist). It stops the production of sex hormones (testosterone and oestrogen) and is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction.
It is available as a 1-month depot and a long-acting 3-month depot. Both depots are used for the treatment of prostate cancer, endometriosis and uterine fibroids but only the 1-month depot is approved for breast cancer, endometrial thinning and assisted reproduction.
Goserelin is marketed by AstraZeneca with the brand name Zoladex. It was first launched in 1987 and is currently the second-largest selling LHRHa in the world. It is currently available in more than one hundred markets.
More on [ Goserelin ]

Zoladex - Official site from AstraZeneca with information for health professionals and patients.
Meta Description: [ Prostate cancer info on prostate cancer education, prostate cancer support, and prostate cancer diagnosis including male hormone therapy, antiandrogens, and psa tests. ]
| David Cook Announces the Death of his brother Adam Cook | |
| Next Video | |